JW Therapeutics, a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in China . Relmacabtagene autoleucel injection (relma-cel) was approved as a third-line therapy for adult patients with relapsed or refractory LBCL. Relma-cel is the first China developed CAR-T product approved for China use and the sixth approved CAR-T product globally. It will be marketed under the trade name Carteyva®. JW is a joint venture of Juno Therapeutics (now a Bristol Myers Squibb company) and WuXi AppTec. More detail.... Stock Symbols: (HK: 2126) (SHA: 603259; HK: 2359) Share this with colleagues: // //